Novavax amends Takeda COVID vaccine pact; gets $19.5M upfront, tiered royalties

NOVAVAX INC

Upfront payment $19.5M from Takeda; $5M creditable against royalties for Takeda FY2024.
Annual $2M service fee plus $8M milestone if Takeda gets marketing approval; $5M of milestone creditable.
Profit share replaced with tiered royalty on net sales in mid-to-high teens, effective April 1, 2024.
Takeda may develop a different vaccine strain but must procure it from Novavax.
Parties also entered release agreement settling all claims related to original 2021 pact.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.